ניתן לחפש לפי שם התרופה באנגלית / עברית, או לפי חומר פעיל
(מינימום 3 אותיות)

Loading...

דוסטאקסל ונוס פארמה 20 מ"ג/מ"ל

DOCETAXEL VENUS PHARMA 20 MG/ML

פרטים כלליים

שם

Name

דוסטאקסל ונוס פארמה 20 מ"ג/מ"ל

DOCETAXEL VENUS PHARMA 20 MG/ML

יצרן

VENUS PHARMA GMBH, GERMANY

בעל רישום

TRUSTPHARM LTD, ISRAEL

שימוש

צורת מינון

Dosage Form

תרכיז להכנת תמיסה לאינפוזיה

CONCENTRATE FOR SOLUTION FOR INFUSION

דרך מתן

Usage Form

תוך-ורידי

I.V

תמונה חסרה

מחירים לצרכן

לא נמצא מידע

חומר פעיל

חומר פעיל

כמות

DOCETAXEL

20 MG/ML

תרופות אחרות בעלות אותם מרכיבים

ATC

שם

L01CD02

קוד

TAXANES

עלונים

לא נמצא מידע

עדכון רישום

לא נמצא מידע

התוויה מאושרת

Breast cancer: Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. Docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. Docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy.Previous chemotherapy should have included an anthracycline or an alkylating agent. Docetaxel in combination with trastuzumab is indicated for treatment of patients with metastatic breast cancer whose tumors overexpressed HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Doxorubicin and cyclophosphamide followed by Docetaxel in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node positive or high-risk node-negative, breast cancer. Docetaxel in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high-risk node-negative, breast cancer.Non-small cell lung cancer: Docetaxel is indicated for the treatment of patients with advanced non-small cell lung carcinoma.Ovarian cancer: Docetaxel is indicated for the treatment of metastatic carcinoma of the ovary after failure first line or subsequent chemotherapy.Prostate cancer: Docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Esophageal cancer: Docetaxel for the treatment of esophageal cancer.Gastric cancer: Docetaxel for the treatment of advanced gastric cancer.Head and neck (SCCHN): Docetaxel as monotherapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.Docetaxel in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

בסל הבריאות

לא

מספר רישום

175-12-37136-99

תנאי ניפוק

תרופה במרשם

מגבלות

ללא הגבלות

אתר המידע התרופתי של ארגון הרוקחות בישראל